Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter

Market Access Monitor

Service of monitoring key reimbursement and HTA developments for medical devices, in-vitro diagnostic tests, and digital technologies in Europe and globally

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Companion diagnostic tests
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
See all tags

Join MTRC at the European Digital Technology and Software Conference in Rotterdam, 30-31 October 2025

MTRC is pleased to announce its participation in the European Digital Technology and Software Conference, taking place 30-31 October 2025 in Rotterdam, the Netherlands.

Our Director, Dr. Oleg Borisenko, will represent MTRC at the event and will be available at the conference to discuss your company’s needs in European Market Access, Health Economics, and Evidence Synthesis services for complex MedTech challenges.

As part of the conference program, Dr. Borisenko will deliver a presentation titled “Healthcare Market Access and Reimbursement in the Age of AI” on Thursday, 30 October 2025, from 12:15 PM to 1:15 PM CET. The session will deliver key insights on typical market access challenges and opportunities for AI technologies across different technology segments (health apps, digital platforms, and imaging AI), market access strategies, evidence requirements from a market access perspective, innovative payment schemes, and case studies of successful AI technologies.

If you would like to schedule a meeting in advance, please contact us at info@mtrconsult.com.

We look forward to connecting with you in Rotterdam!

Tags
Services of MTRC

The latest related news

10
Oct 2025

Bi-weekly snapshot of market access and HEOR project work at MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of October 06th, we plan to work on 20 projects. Review the complete list of planned activities in this post.
Read more
10
Oct 2025

MTRC has released a White Paper "Innovation Funding (Forfait Innovation) for Medical Technologies in France”

MTRC has released a White Paper titled "Innovation Funding (Forfait Innovation) for Medical Technologies in France”. This White Paper provides a comprehensive overview of the Innovation Funding (Forfait Innovation) program. It describes the scheme’s objectives, eligibility criteria, funding structure, and the decision-making process with regulated timelines. It also outlines the roles of stakeholders, clinical and economic evidence requirements, and the outcomes of applications since the program’s launch in 2015. In addition, this document presents a case study of the METAglut1 test, illustrating the pathway from Innovation Funding to permanent reimbursement inclusion under NABM.
Read more
22
Sep 2025

Bi-weekly snapshot of market access and HEOR project work at MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of September 22nd, we plan to work on 25 projects. Review the complete list of planned activities in this post.
Read more
18
Sep 2025

MTRC has released a White Paper "Evidence Requirements for Non-IVD Diagnostic Technologies under NICE’s HealthTech Programme”

MTRC has released a White Paper titled "Evidence Requirements for Non-IVD Diagnostic Technologies under NICE’s HealthTech Programme". This white paper reviews five assessments of non-IVD diagnostic technologies conducted under the former Diagnostics Assessment Programme (DAP) framework. Despite procedural changes, the case studies offer enduring insights into NICE’s evidence expectations and key factors influencing recommendation outcomes. These findings can help inform evidence generation strategies and support market access planning for similar technologies under the current HealthTech framework.
Read more